A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03329508 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 6, 2017
Last Update Posted : May 4, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
P2B001 is an investigational drug that comprised of low doses of two drugs, pramipexole and rasagiline, which are both approved drugs and routinely used in standard therapy for Parkinson's disease. The two drugs work in two different mechanisms that help each other, so there is a reason to believe that their combined activity will be better than each individual drug, and that lower doses can be used without losing the therapeutic effect. Thus, the development of P2B001 is intended to provide a combination of low doses of these two drugs, in an improved formulation, that is hoped to be more effective in controlling Parkinson's disease symptoms and with less side effects than each of the drugs taken alone or the current available commercial drugs taken together. In a previously completed clinical trial a significant improvement in Parkinson's disease symptoms was seen in patients treated with P2B001 compared to patients that were treated with placebo.
In this phase 3 study , the safety and efficacy of P2B001 will be assessed by comparing P2B001 to its individual components pramipexole and rasagiline. This will be done by monitoring the motor and non-motor symptoms, evaluating responses participants provide on questionnaires relating to Parkinson's disease and quality of life that will be completed on every visit. In addition, this study will also compare P2B001 to a marketed drug of pramipexole ER. Approximately 525 patients will participate in this research study and the participation in this study will last between 14 to 18 weeks.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Parkinson Disease Early Parkinson's Disease | Drug: P2B001 Drug: Rasagiline Drug: Pramipexole Drug: Pramipexole ER | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 525 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | 4 arms |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Masking Description: | double blind study |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER. |
| Actual Study Start Date : | January 29, 2018 |
| Estimated Primary Completion Date : | August 31, 2021 |
| Estimated Study Completion Date : | October 31, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: P2B001
Fixed dose combination once daily capsule of pramipexole and rasagiline
|
Drug: P2B001
Fixed dose once daily combination capsule of pramipexole and rasagiline
Other Name: Fixed dose combination of Pramipexole and rasagiline |
|
Experimental: rasagiline capsule
rasagiline Once daily capsule
|
Drug: Rasagiline
Rasagiline oral capsule
Other Name: rasagiline capsule |
|
Experimental: Pramipexole capsule
Pramipexole once daily capsule
|
Drug: Pramipexole
Pramipexole low dose oral capsule
Other Name: Pramipexole capsule |
|
Active Comparator: Pramipexole Extended Release
pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg
|
Drug: Pramipexole ER
Pramipexole ER titrated to optimal dose
Other Name: Pramipexole Extended Release Oral Tablet |
- change in total Unified Parkinson's Disease Rating Scale (UPDRS) score (defined as sum of parts II and III, scores (0-160). [ Time Frame: baseline to week 12 ]Superiority of P2B 0.6/0.75 mg as compared to its individual components in the change of total UPDRS score (defined as sum of parts II and III, scores (0-160).
- Change in Epworth Sleepiness Scale (ESS) score. [ Time Frame: baseline to week 12 ]Superiority of P2B 0.6/0.75 mg as compared to pramipexole ER in the change of Epworth Sleepiness Scale (ESS) score.
- change of Total Parkinson's Disease Questionnaire 39 (PDQ39) score. [ Time Frame: baseline to week 12 ]The efficacy of P2B 0.6/0.75 mg as compared to its individual components in the change of Total PDQ39 score.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 35 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject has Parkinson's disease consistent with the UK Brain Bank Criteria and must have bradykinesia with sequence effect. If rest tremor does not exist must have prominent asymmetry of motor function.
- Subject with disease duration less than 3 years since diagnosis.
- Subject has a H&Y stage score of < 3.
- Subject has a MMSE score ≥ 26.
Exclusion Criteria:
- Subject has an atypical parkinsonian syndrome or secondary parkinsonism
- Subject has previous exposure to levodopa or a dopamine agonist for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 2 months prior to the baseline visit.
- Subject has previous exposure to a MAO-B inhibitor for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 3 months prior to the baseline visit.
- Subject who has taken anticholinergic drugs for PD or amantadine for longer than 4 weeks; if previous exposure was less than 4 weeks then it must not be within 1 month prior to the baseline visit.
- Subject has moderate (Child-Pugh categorization B, score 7-9) or severe (Child-Pugh categorization C, score 10-15) hepatic impairment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03329508
Show 72 study locations
| Study Director: | Pninit Litman | Pharma2b LTD |
| Responsible Party: | Pharma Two B Ltd. |
| ClinicalTrials.gov Identifier: | NCT03329508 |
| Other Study ID Numbers: |
P2B001/003 |
| First Posted: | November 6, 2017 Key Record Dates |
| Last Update Posted: | May 4, 2021 |
| Last Verified: | September 2020 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Parkinson disease early Parkinson's Disease Parkinson's diagnosis Parkinson's tretment Parkinson's medications |
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases Pramipexole Rasagiline Antioxidants |
Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agonists Dopamine Agents Neurotransmitter Agents Monoamine Oxidase Inhibitors Enzyme Inhibitors Neuroprotective Agents |